Singleron Biotechnologies

Executive Summary

Singleron Biotechnologies is a German life sciences company providing end-to-end solutions for single-cell sequencing and multi-omics analysis. Founded in 2017 and headquartered in Göttingen, the company offers a comprehensive portfolio including proprietary instruments, consumable kits, bioinformatics software, and contract research services. By enabling researchers and clinicians to derive deep cellular insights, Singleron aims to accelerate precision medicine applications. Despite being private with limited public financials, the company has established a presence in the rapidly growing single-cell genomics market, which is driven by increasing demand for high-resolution cellular profiling in oncology, immunology, and drug development. Singleron's integrated platform approach differentiates it from competitors by offering a seamless workflow from sample preparation to data analysis. The company's ability to scale adoption and form strategic partnerships will be key to its growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of next-generation single-cell multi-omics platform70% success
• Q2 2027Strategic partnership with a major pharmaceutical company for precision oncology50% success
• Q3 2026Series B funding round to expand global commercial footprint80% success